Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years. Their administration represents a new approach compared to the previous, long-established treatment, and has significantly changed the prognosis of the disease in many patients.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
